The FDA just gave Axsome Therapeutics Inc. (Axsome (AXSM)) a big new arrow for its quiver. On Thursday, the agency approved Auvelity (dextromethorphan HBr and bupropion HCl) for agitation tied to dementia due to Alzheimer's disease. That's a huge deal because agitation—ranging from restlessness to outright verbal and physical aggression—happens in up to 76% of people with Alzheimer's. And with more than 7 million Americans living with the disease, this is one of the most challenging and costly aspects of care.

Auvelity is already approved for major depressive disorder in adults, where it got Breakthrough Therapy designation and Priority Review. The company says it's been used in over 300,000 patients across clinical and real-world settings. Now it's got a second act.

How It Works

Auvelity is a first-in-class therapy that targets N-methyl D-aspartate (NMDA) and sigma-1 receptors in the brain. The dextromethorphan component does the heavy lifting on those receptors, while bupropion boosts dextromethorphan levels by inhibiting the CYP2D6 enzyme. It's a clever bit of pharmacology.

The Data That Got It Approved

The FDA's decision rested on two Phase 3 trials: ADVANCE-1 and ACCORD-2. In ADVANCE-1, Auvelity showed statistically significant improvement in agitation symptoms versus placebo, measured by the Cohen-Mansfield Agitation Inventory (CMAI) total score. More patients also showed clinical improvement on a key secondary measure. ACCORD-2 was a longer-term randomized withdrawal study: patients who stayed on Auvelity had a significantly longer time to relapse compared with those switched to placebo. That's the kind of data that makes regulators nod.

The Market Opportunity

William Blair sees this as a major commercial opportunity, projecting peak sales above $2.1 billion for the Alzheimer's agitation indication alone—right in the middle of management's $1.5 billion to $3 billion estimate. The competitive landscape is wide open: Rexulti, the only other FDA-approved treatment for Alzheimer's agitation, held just a 4.6% market share as of end-2025, according to Lundbeck. So there's plenty of room.

Pipeline Moves

Axsome hasn't been sitting still. In April, it agreed to get exclusive global rights to TAK-063 (balipodect) from Takeda Pharmaceutical Co Ltd (Takeda (TAK)). Axsome plans to develop this selective PDE10A inhibitor for schizophrenia and Tourette syndrome, with Phase 3 trial-enabling activities for schizophrenia starting this year. Takeda got an undisclosed upfront payment and is eligible for milestone payments.

And in February, Axsome dosed the first patient in the CLARITY Phase 3 trial of solriamfetol for major depressive disorder with excessive daytime sleepiness symptoms. So the pipeline is chugging along.

Stock Action

Axsome shares were up 0.12% at $208.00 in premarket trading Friday. Over the past month, the stock has gained about 22%, versus a 9.9% rise in the S&P 500. Year-to-date, it's up roughly 13%, compared to the index's 4.8% gain. Not bad for a company that just opened up a billion-dollar market.